Ieq Capital LLC acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 440 shares of the company's stock, valued at approximately $271,000.
A number of other large investors have also made changes to their positions in the stock. Stifel Financial Corp raised its holdings in argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after acquiring an additional 1,170 shares during the last quarter. FMR LLC grew its position in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Simplify Asset Management Inc. increased its stake in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after purchasing an additional 944 shares during the last quarter. Stephens Inc. AR purchased a new position in argenx during the fourth quarter worth about $310,000. Finally, Ritholtz Wealth Management boosted its stake in argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after buying an additional 414 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on ARGX shares. HC Wainwright upped their price objective on shares of argenx from $717.00 to $720.00 and gave the company a "buy" rating in a research note on Friday. JMP Securities upped their price target on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Wedbush reiterated an "outperform" rating and issued a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Scotiabank upgraded argenx from a "sector perform" rating to a "sector outperform" rating and upped their price objective for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Finally, Oppenheimer increased their target price on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx currently has a consensus rating of "Moderate Buy" and a consensus target price of $662.83.
Check Out Our Latest Stock Report on argenx
argenx Trading Up 0.1 %
ARGX stock traded up $0.55 during trading on Tuesday, reaching $623.16. The stock had a trading volume of 164,946 shares, compared to its average volume of 270,684. The firm has a fifty day moving average price of $642.51 and a 200 day moving average price of $591.91. The company has a market capitalization of $37.86 billion, a P/E ratio of -708.78 and a beta of 0.58. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Sell-side analysts predict that argenx SE will post 3.13 EPS for the current year.
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
